The research company Curasight reports encouraging preliminary data from the first patient treated with the drug candidate uTreat in the ongoing phase 1 study in patients with high-grade gliomas. "PET images (Position Emission Tomography) from the first treated patient showed clear and persistent uptake of uTreat in the tumor, confirming that the drug successfully targets cancer tissue," the company writes in a press release.Curasight adds that the signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The company goes on to state that the preliminary readout of uTreat was in line with expectations and that more patients are being enrolled, with top-line data expected to be presented in the second quarter of 2026.